Medical Marijuana Resked: Implications for Insurance Coverage, Capacity and Compliance.

The article focuses on the Department of Justice’s April 23 order rescheduling state-licensed medical marijuana and FDA-approved cannabis products to Schedule III of the Controlled Substances Act (CSA), which narrows but does not eliminate federal prohibitions. This rescheduling is expected to improve financial and regulatory conditions for medical cannabis operators by removing Internal Revenue Code Section 280E restrictions, enhancing banking access, and encouraging insurers to expand coverage and reinsurance capacity. However, challenges remain due to ongoing federal-state regulatory misalignment, lack of FDA standards for state medical marijuana products, and transitional underwriting risks. The insurance market is anticipated to grow gradually, with excess and surplus (E&S) carriers leading while admitted markets cautiously expand as federal guidance evolves. [Extracted from the article]